“Our price target of $6/share is based on an equally weighted composite of: (a) $6.62/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.57 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2018-2024 of $4.46/share (discount rate 12%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Firdapse to secure regulatory approval in the US; and (2) failure of Firdapse to achieve peak commercial revenue estimates in our model due to market size, penetration rates, and/or pricing.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 12.3% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Catalyst Pharma with a $6.60 average price target, implying an 114.3% upside from current levels. In a report issued on October 26, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $8 price target.
Based on Catalyst Pharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $7.84 million. In comparison, last year the company had a GAAP net loss of $4.18 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder.
Read More on CPRX:
- Catalyst Pharmaceuticals (CPRX): We Are Confident of Firdapse’s Approvability, Says Analyst
- Oppenheimer Pounds the Table on Catalyst Pharmaceuticals (CPRX) Ahead of Upcoming FDA Decision
- Why Analysts See Solid Upside Potential for Ocular Therapeutix (OCUL), Catalyst Pharmaceuticals (CPRX), and AcelRx (ACRX)
- Cantor Sees Strong Upside in Catalyst Pharmaceuticals (CPRX) Shares, Sets an $8 Price Target